The authorised generics will launch at a list price of USD 24,000 for the most common course of therapy and will be available in January 2019.
Since the launch of Gilead's first HCV medication in 2013, the average price paid for each bottle of medicine in the United States has decreased by more than 60% off of the public list prices, across health insurers and government payers.
Due to the complexity and structure of the US healthcare system, however, these discounts provided by Gilead may not always translate into lower costs for patients.
Further, existing contracts, together with laws associated with government pricing policies, make it challenging to quickly lower a product's list price once it is on the market.
The authorised generics are priced to more closely reflect the discounts that health insurers and government payers receive currently.
Insurers will have the choice of offering either the authorised generics or the branded medications for both Epclusa and Harvoni.
In the Medicare Part D setting, the authorized generics could save patients up to USD 2,500 in out-of-pocket costs per course of therapy.
The authorised generics will also offer substantial savings to state managed Medicaid plans that do not currently benefit from negotiated rebates and that represent a significant number of people in need, potentially opening up access to our medications to beneficiaries who were previously denied coverage.
Beyond the company's efforts to reduce patient costs, Gilead is continuing to pursue innovative collaborations and long-term financing models, such as a potential subscription model, that could not only expand access, but aim to eliminate HCV in the United States and around the world.
Gilead Sciences has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical